Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 2644
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 10  |  Issue : 6  |  Page : 2381-2385

Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure


1 Civil Surgeon Office, Munshiganj, Bangladesh
2 Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
3 Department of Hepatology, Dhaka Medical College Hospital, Dhaka, Bangladesh
4 Department of Anatomy and Embryology, Ehime University Graduate School of Medicine, Ehime, Japan
5 Department of Primary Care and Microbiology, Brahminbaria Medical College, Brahminbaria, Bangladesh
6 Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan

Correspondence Address:
Dr. Mamun A Mahtab
Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Bangladesh. Postal Address: House # 109, Road # 4, Block # B, Banani, Dhaka - 1213
Bangladesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jfmpc.jfmpc_2302_20

Rights and Permissions

Introduction: ACLF is characterized by acute deterioration of liver function in patients with chronic liver disease. HBV is one of the most important causes of both acute insult and underlying chronic liver disease in ACLF. Reactivation of HBV is one of the common causes of ACLF in our region. ACLF requires multiple organ support and is associated with high short and medium term mortality. This is the reason why early, rapid reduction of HBV DNA is essential in treating ACLF-B. Methods: Consecutive patients of ACLF-B due to spontaneous reactivation of HBV (ALT> 5xULN or >2 x baseline and HBV DNA >20,000 IU/ml) were randomized into tenofovir group (300mg/day) and telbivudine group (600mg/day) along with standard medical treatment. Clinical and laboratory parameters were evaluated at baseline, day-7, day-14, day-30 and day-90. HBV DNA was evaluated at baseline and after three months of therapy. Primary end point was survival or death at three months. Secondary end point was improvement of liver function assessed by Child-Turcotte Pugh score and MELD score at three months. Results: 30 patients were enrolled in the study and 15 of them received tenofovir and 15 patients received telbivudine. Most of the baseline parameters showed no difference except serum AST and serum creatinine level that showed statistically significant difference between two groups. After antiviral therapy both groups showed significant clinical improvement along with CTP and MELD scores. However statistically significant improvement between tenofovir and telbivudine groups was only seen with MELD score. Survival rate was 80% in tenofovir group and 60% in telbivudine group, but this was not statistically significant. Low serum albumin at baseline was predictor of mortality. Conclusion: In patients of ACLF-B, antiviral therapy with both tenofovir and telbivudine improve liver function, but there is no statistically significant difference in survival between tenofovir and telbivudine.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed246    
    Printed4    
    Emailed0    
    PDF Downloaded35    
    Comments [Add]    

Recommend this journal